Abstract

PHONE INTERVIEW FOR ASSESSMENT OF EFFECT OF OMALIZUMAB IN ASTHMA PATIENTS WITH IGE PHENOTYPE AT A TERTIARY CENTRE IN INDIA

Sonam Dolma*, Thenzin V Jubil, Benajir Aktar, Srivatsa Lokeshwaran, Nitesh Gupta, Praveen Kumar and Dr. Mahesh N. M.

.

Abstract

Background: In developing countries, the prevalence of asthma has increased in association with increased urbanization. Approximately 5% patients have severe asthma which remains uncontrolled even on treating with a long acting bronchodilator and a high dose inhaled corticosteroids. The aim of the study was to assess the effect of omalizumab in asthma patients with IgE phenotype using ACT. Objectives: To assess symptomatic and functional improvement before and after taking omalizumab injection. To monitor compliance to the therapy, no. of exacerbations while taking the therapy and ADE associated with injection omalizumab. Method: A retrospective observational study was conducted in 26 patients of age 12 years and above, who were prescribed omalizumab from the year 2018 to 2022. Result: In our study, the prevalence of asthma of IgE phenotype was higher in females than males. The effectiveness of omalizumab was found to be similar in patients with IgE levels 300 kUI/L. Most patients experienced significant improvement in ACT scores one month post completion of omalizumab treatment, when compared to a month before initiating omalizumab; and significant reduction in exacerbations, symptomatic and functional improvement was seen in many patients who were poorly controlled at the beginning of the study and became well controlled by the end. Also corticosteroid usage was decreased after providing omalizumab treatment. Conclusion: Symptomatic and functional improvement was noticed post omalizumab therapy which proves its efficacy in patients with allergic asthma of IgE phenotype.

Keywords: ACT- asthma control test, IgE- immunoglobulin E, ADE- adverse effects.